Zydus Lifesciences reported a strong performance for the financial year ended March 31, 2026. The company achieved a consolidated net profit of ₹50,400 million, supported by a total revenue of ₹271,484 million. Reflecting confidence in its long-term strategy, the Board has recommended a final dividend of ₹1 per equity share (100%), subject to shareholder approval. The company continues to focus on strengthening its global footprint through strategic acquisitions and operational growth.
Financial Performance Overview
For the financial year ended March 31, 2026, Zydus Lifesciences recorded a consolidated net profit of ₹50,400 million, demonstrating significant growth from the previous year. The company’s total revenue from operations for the full year stood at ₹271,484 million, driven by steady growth across its key business segments.
Segment Performance Highlights
The company continues to derive the majority of its revenue from its Pharmaceuticals segment, which contributed ₹224,121 million to the annual top-line. The Consumer products segment also showed strong performance, adding ₹39,540 million, while the Medical technologies division contributed ₹7,823 million during the year.
Strategic Developments and Expansion
Zydus Lifesciences has been actively expanding its capabilities through strategic initiatives. Significant milestones include the full acquisition of Amplitude Surgical SAS in France, the purchase of Comfort Click Limited, and the acquisition of two U.S.-based biologics manufacturing facilities from Agenus. Additionally, the company has signed an agreement to acquire Assertio Holdings, Inc., further bolstering its global acquisition strategy.
Dividend and Shareholder Value
Reflecting on the year’s success, the Board of Directors has recommended a final dividend of ₹1 per equity share, representing a 100% payout on the face value of the shares. The final approval for this dividend is expected at the upcoming Annual General Meeting, scheduled for August 11, 2026.
Source: BSE
